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Summary
 
Quiescent endothelial cells (EC) regulate blood flow and prevent intravascular thrombosis.
This latter effect is mediated in a number of ways, including expression by EC of thrombo-
modulin and heparan sulfate, both of which are lost from the EC surface as part of the activa-
tion response to proinflammatory cytokines. Loss of these anticoagulant molecules potentiates
the procoagulant properties of the injured vasculature. An additional thromboregulatory factor,
ATP diphosphohydrolase (ATPDase; designated as EC 3.6.1.5) is also expressed by quiescent
EC, and has the capacity to degrade the extracellular inflammatory mediators ATP and ADP to
AMP, thereby inhibiting platelet activation and modulating vascular thrombosis. We describe
here that the antithrombotic effects of the ATPDase, like heparan sulfate and thrombomodulin,
are lost after EC activation, both in vitro and in vivo. Because platelet activation and aggrega-
tion are important components of the hemostatic changes that accompany inflammatory dis-
eases, we suggest that the loss of vascular ATPDase may be crucial for the progression of vascu-
lar injury.
 
Q
 
uiescent vascular endothelial cells (EC)
 
1
 
, as they nor-
mally exist in vivo, function primarily to regulate
blood flow and hemostasis by the maintenance of a non-
thrombogenic surface (1). These effects are mediated largely
by protease inhibitors such as antithrombin, which interacts
with glycosaminoglycans, including heparan sulfate (2); con-
currently, there is also expression of thrombomodulin that
binds thrombin and induces the protein C/protein S anti-
coagulant pathway (3). Activation of EC promotes vascular
thrombosis by the simultaneous induction of procoagulant
activity (4, 5) and the suppression of anticoagulant proper-
ties (6–8). In particular, both heparan sulfate (9) and throm-
bomodulin (10) are rapidly lost from the surface of the EC.
Platelet activation and aggregation are important factors
in the mediation of vascular inflammation (6, 11, 12) and
are specifically associated with the rejection of discordant
xenografts, even in the absence of complement activation in
a process termed delayed xenograft rejection (13). Progres-
sion of platelet recruitment in association with activation is
enhanced by adenosine nucleotides, which are released
from damaged endothelium or other vascular cells, and are
secreted in high concentrations by platelets in response to
exogenous ADP, collagen, thrombin, or activated comple-
ment components. This provides an important positive
feedback mechanism (11, 14). A critical regulatory element
in the control of platelet thrombus formation may be the
expression on endothelium of an ATP diphosphohydrolase
(ATPDase) (15–17). Enzymatic degradation of extracellular
ATP and ADP to AMP by this ecto-enzyme would trans-
form and reverse the proinflammatory environment brought
about by interaction with purinergic receptors on platelets
and vascular endothelium. The ultimate generation of ade-
nosine results in a platelet anti-aggregatory signal and
downregulation of vascular inflammation in conjunction
with production of prostaglandin I
 
2
 
 and nitric oxide (NO)
(11, 18, 19).
Our interest in platelet activation in the setting of discor-
dant xenograft rejection (20, 21) has led us to study the ex-
tent to which vascular ATPDase is modulated by EC acti-
vation and inflammatory mediators. Here, we show that
the antithrombotic effect of the ATPDase, like heparan sul-
 
1
 
Abbreviations used in this paper:
 
 ATPDase, ATP diphosphohydrolase; EC,
endothelial cells; FBS, fetal bovine serum; hEC, human aortic EC; HRP,
horseradish peroxidase; HUVEC, human umbilical vein EC; NO, nitric
oxide; PAF, platelet activation factor; pEC, pig aortic EC; SOD, superox-
ide dismutase.
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fate and thrombomodulin, is lost following EC activation,
both in vitro and in vivo.
We speculate that this loss, and the resultant decreased
capacity to degrade ADP, could play a significant role in
the extensive platelet activation and vascular inflammation
seen in reperfusion processes, xenograft rejection, and other
forms of vascular injury. We have recently shown common
identity between CD39 and the vascular EC ATPDase (22).
We propose that the now feasible expression of the CD39/
ATPDase in a form that is not inhibited during EC activation,
as done for thrombomodulin (23), may find therapeutic ap-
plication as a valuable and novel antithrombotic agent.
 
Materials and Methods
 
Reagents
 
Ammonium molybdate, catalases (bovine liver), collagenases,
bovine hemoglobin, dipyridamole, flutamine, malachite green, strep-
tomycin-penicillin, superoxide dismutases (bovine erythrocyte), tryp-
sin, Tween 20, and xanthine were bought from Sigma Chemical
Co. (St. Louis, MO). ATP, ADP, and thrombin were purchased
from Calbiochem Corp. (La Jolla, CA). DMEM, HBSS, RPMI,
10
 
3
 
 PBS, fetal bovine serum (FBS; Lot#44N4044)), penicillin
G–streptomycin, L-glutamine (200 mM), and EDTA-trypsin (5.3
mM/0.5%) were from GIBCO BRL (Gaithersburg, MD). Xanthine
oxidase from bovine milk and ADP-
 
b
 
-S were from Boehringer
Mannheim GmbH (Mannheim, Germany and Indianapolis, IN,
respectively). Des-methyl tirilazad was a gift from The Upjohn
Company  (Kalamazoo, MN). Recombinant, human TNF
 
a
 
 was a
product of Sandoz Pharma, Ltd. (Basel, Switzerland). Collagen
was from Chrono-Log Corp. (Havertown, PA). Agarose was
from FMC Corp. (Rockland, ME). ECL enhanced luminol
chemiluminescent substrate and hybond-PVDF membranes were
from Amersham Corp. (Arlington Heights, IL), and X-OMAT
LS film from Kodak (Rochester, NY).
 
Antibodies
 
Control mAb’s IgG
 
1
 
-biotin and streptavidin-PE were products of
PharMingen (San Diego, CA); IgG
 
1
 
-FITC, IgG
 
2a
 
-FITC, IgG
 
2a
 
-PE
were from Becton Dickinson (San Jose, CA). Anti–human CD39
mAb (Immunotech, Westbrook, ME, and Accurate Chem. &
Sci. Corp., Westbury, NY), and anti–mouse IgG conjugated with
either peroxidase or fluorescein-5-isothiocyanate (Sigma Chemical
Co., St. Louis, MO) were used. Peroxidase conjugated antibod-
ies, biotinylated goat anti–mouse IgG, and streptavidine–horseradish
peroxidase (HRP) were purchased and used at recommended di-
lution (Pierce Chem. Co., Rockford, IL). Anti–TNF
 
a
 
 mAb used
as isotype control antibody was from Endogen (Boston, MA).
A 16–amino acid peptide from the NH
 
2
 
 terminus of the por-
cine pancreatic ATPDase (KSDTQETYGALDLGGA) with com-
mon sequence homology to human CD39 was used for the gen-
eration of rabbit polyclonal antibody (gift of Dr. A.D. Beaudoin,
University of Sherbrooke, Sherbrooke, Quebec). We found that
these polyclonal antibodies react with human CD39/ATPDase
expressed by COS-7 transfectants (22).
 
Endothelial Cell Culture and Platelet Preparation
 
Pig aortic endothelial cells (pEC), harvested by a combined
collagenase and scraping technique from adolescent male pig aortae,
were cultured in DMEM supplemented with 10% FBS, L-glutamine
(2 mM), penicillin G (50 U/ml), and streptomycin (50 
 
m
 
g/ml).
These pEC were characterized by E-selectin expression after activa-
tion, and by morphological assessment under phase microscopy (24).
Human aortic EC (hEC), purchased from Cell Systems Corp.
(Kirkland, WA), were characterized by acetylated-LDL uptake,
positive staining for factor VIII/vWF, and angiotensin converting
enzyme activity. Human EC culture medium (CS-3.0) contain-
ing heparin (15 
 
m
 
g/ml) and acidic fibroblast growth factor (50
 
m
 
g/ml) with hEC passaging reagents, EDTA, trypsin, and trypsin
inhibitor were also obtained from Cell Systems Corp. DMEM
(GIBCO BRL, Gaithersburg, MD) supplemented with 10% FBS,
L-Glutamine (2 mM), penicillin G (50 U/ml) and streptomycin
(50 
 
m
 
g/ml) was used for the culture of hEC before exposure to
oxidative stress. Human umbilical vein EC (HUVEC) at the third
passage were from Dr. B.M. Ewenstein (Brigham and Women’s
Hospital, Boston, MA). Where indicated, EC were preactivated
by TNF
 
a
 
 stimulation at 10 and 50 ng/ml for determined times
before harvesting (25).
Aortic EC at 
 
z
 
passage 5 were prepared in suspension by
EDTA-collagenase treatment (17, 26). After detachment, EC
were reconstituted with an equal volume of culture medium con-
taining FBS, and then pelleted by centrifugation at 150 
 
g
 
 for 8
min at 22
 
8
 
C. Cells were then resuspended in 5 mM Hepes saline,
pH 7.4, 5 mM KCl, and 1 mM CaCl
 
2
 
 with 1 mM MgCl
 
2
 
. They
underwent two more wash cycles before final reconstitution at 5 
 
3
 
10
 
6
 
/ml and maintained at 22
 
°
 
C. EC suspensions had a viability of
in excess of 90% by trypan blue exclusion.
Blood anticoagulated with 0.1 vol of 3.2% sodium citrate was
collected from apparently healthy, drug free human volunteers
after obtaining informed consent. Washed, gel filtered platelets,
and platelet rich plasma were prepared by standard methodology
(27, 28).
 
Platelet Aggregation Experiments with Combined 
Suspensions of Platelets and EC
 
Platelet aggregation and ATP release tests used a two sample,
four channel, Whole Blood Lumi-Aggregometer (560 Ca; Chrono-
Log Corp.). Platelets (2 
 
3
 
 10
 
8
 
) and EC (10
 
6
 
) were preincubated
in siliconized cuvettes containing stirring bars at 37
 
8
 
C in the ag-
gregometer. Control cuvettes contained equal numbers of human
and porcine EC and the platelet–EC combinations, to correct for
light absorption by the nonaggregating EC. Platelets were acti-
vated by ADP (1–5 
 
m
 
M), equine collagen (1–5 
 
m
 
g/ml) (Chrono-
Log Corporation), or human thrombin (0.1 U/ml). Platelet ag-
gregation was determined by increased light transmission (changes
in OD representing aggregation), and by release of ATP (lumi-
nometry) following manufacturer’s instructions (Chrono-Log
Corp.).
 
Investigation of EC–Mediated Inhibitory Mechanisms
 
The influence of prostenoids and NO was determined by eval-
uating pEC inhibitory responses in the presence of prostaglandin
synthetase inhibitors (aspirin and indomethacin) and scavengers
of NO (hemoglobin), or by methylene blue that prevents effects of
NO by inhibiting soluble guanylate cyclase (17). Specifically, platelet
donors had blood drawn 12 h after taking 650 mg aspirin, and EC
cultures were treated with 1 mM acetyl salicylic acid for 30 min un-
der standard culture conditions. After resuspension, 10 
 
m
 
M in-
domethacin was added before study. A final concentration of 10 
 
m
 
M
methylene blue was added to the platelets and incubated at room
temperature for 30 min followed by a 15 min centrifuge at 1,450 
 
g
 
at 4
 
8
 
C before resuspension. Oxyhemoglobin was prepared from 
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bovine hemoglobin according to the method described by Martin et
al. (29), and added to EC suspensions at 25 
 
m
 
M. The effects of an
ATPDase resistant nonmetabolizable ADP analog (ADP-
 
b
 
-S) on
platelet aggregation in the presence of EC was also studied.
 
Endothelial Cell ATPDase Assays
 
Biochemical ATPase Assays After Method of Le Bel.
 
Intact pEC
or hEC preparations were incubated with 5–200 
 
m
 
M ADP or
ATP, and free phosphate release was determined over time (30).
Copper acetate, pH 4.0, and 5% ammonium molybdate with
Elon 2% in 5% sodium sulfite were added to the samples, and the
color was allowed to develop for 10 min. Standard curves were con-
structed with an appropriate range of concentrations of KH
 
2
 
PO
 
4
 
for that experiment. Absorbance was measured at 870  nm on a
spectrophotometer (DU-64; Beckman Instruments, Inc., Fuller-
ton, CA).
 
Biochemical ATPase Assay with Malachite Green.
 
Reaction of en-
zyme  was inactivated by the addition of malachite green reactive
(31). Absorbance was read at 610 nm on a microplate spectropho-
tometer (EL 340; Bio-Tek Instruments, Inc., Winooski, VT).
 
TLC of Nucleotides and Nucleosides.
 
EC cultures were incu-
bated with [
 
14
 
C]ADP from 1 to 50 
 
m
 
M (55 mCi/mmol; New
England Nuclear, Boston, MA). Supernatant fluids collected at
determined time points were analyzed for nucleotide degradation
by TLC carried out on linear K preabsorb strip TLC plates
(Whatman Laboratory Division, Clifton, NJ) using a solvent sys-
tem composed of isobutyl alcohol/1-pentanol/ethylene glycol
monoethyl ether/NH
 
4
 
OH/water at ratios 90:60:180:90:120 (17).
The separated compounds were scanned for radioactivity with a
Phosphor-Imager (Molecular Dynamics, Sunnyvale, CA). Differ-
ential degradation of the [
 
14
 
C]ADP was then determined by Im-
ageQuant software according to manufacturer’s instructions.
 
Western Blotting
 
Cell proteins obtained from lysis of EC induced by three cycles
of freeze thawing, were subjected to polyacrylamide gel electro-
phoresis under reducing conditions, blotted onto Hybond-poly-
vinylidene fluoride membranes (32), and probed with polyclonal
antibody directed at the NH
 
2
 
-terminal peptide sequence obtained
from the porcine pancreatic type I ecto-ATPDase (33). This se-
quence corresponds to ETNNQETFGALDLGGA within the
vascular ATPDase/CD39 (sequence identity as underlined); we
have shown that this antibody reacts specifically with human
CD39/ATPDase expressed in COS-7 cells (22). This polyclonal
antibody also cross-reacts with vascular ATPDase (34). Peroxidase
conjugated antibodies were detected using the ECL enhanced lumi-
nol chemiluminescent substrate and X-OMAT LS film.
 
Immunocytofluorometric Analysis of
CD39/ATPDase Expression
 
Human EC were harvested by gentle pipetting with Hanks
balanced salt solution (GIBCO BRL) containing 10 mM EDTA.
Cells were washed with buffer (PBS, 5% FBS, and 0.02% sodium
azide), and incubated with either anti–human CD39 mAb (IgG
 
1
 
)
(Immunotech), or an isotype matched control mAb, anti–TNF
 
a
 
(Endogen) for 30 min on ice. Cells were washed twice and incu-
bated with anti–mouse IgG conjugated with fluorescein-5-iso-
thiocyanate (Sigma Chemical Co.) for 30 min on ice. Finally, cells
were washed twice and analyzed by flow cytometry on a FACScan
 
Ò
 
bench top model using Cellquest II software (Becton Dickinson).
Data were collected from viable cells only, as determined by pro-
pidium iodide uptake.
 
Immunocytochemical Analysis
 
Cells were fixed with 0.05% glutaraldehyde for 15 min, and
CD39/ATPDase antigen was detected by anti–human CD39
mAb (Accurate) using biotinylated goat anti–mouse IgG and
streptavidine-HRP (Pierce) as a detection system. 3-NH
 
2
 
-9-eth-
ylcarbazole (Sigma Chemical Co.) was used as the HRP substrate.
 
Modulation of ATPDases By Cellular Activation and 
Oxidative Stress
 
EC were exposed to TNF
 
a
 
, to H
 
2
 
O
 
2
 
 (100 
 
m
 
M), or xanthine
oxidase (100 mU/ml) and xanthine (50–200 
 
m
 
M), the latter com-
bination created to directly generate oxidative stress with all appro-
priate controls before determination of EC ATPDase activity (35).
The relative role of each oxidant was determined by perform-
ing parallel experiments in the presence of one of the following
individual agents: superoxide radical scavenger SOD (Cu-Zn
form, from bovine erythrocytes, specific activity 3,570 U/mg of
protein used at 330 U/ml), the hydrogen peroxide scavenger cat-
alase (from bovine liver, specific activity 40,000 U/mg of protein
used at 1,000 U/ml), the 21-aminosteroid des-methyl tirilazad
(final concentration 5 
 
m
 
M, an effective inhibitor of membrane
peroxidation), and the iron chelator deferoxamine (100 
 
m
 
M). In
associated experiments, the effect on activated EC ATPDase ac-
tivity of the addition of 
 
b
 
-mercaptoethanol (5 and 10 
 
m
 
M) was
studied. The extent of lipid peroxidation was confirmed by deter-
mination of levels of malonaldehyde and 4-hydroxyalkenals in
cell lysates by a colorimetric assay kit (Calbiochem Corp.).
 
Histology and Histochemistry
 
Biopsies from control rat kidney, or those rendered ischemic
by renal artery occlusion under direct vision for 1 h, and then
reperfused for defined time periods of up to 2 h were studied.
Tissues were snap-frozen in liquid nitrogen and stored at 
 
2
 
80
 
8
 
C,
or fixed in 10% neutral buffered formalin, embedded in paraffin,
and sectioned for light microscopy. Cryostat sections were treated
according to the cerium based method as previously described
(36). In brief, cryostat sections were fixed with pararosaniline
with NaNO
 
2
 
 and preincubated in Tris-maleate buffer with CeCl
 
3
 
and Mg(NO
 
3
 
)
 
2
 
 (Sigma Chemical Co.). Sections were then incu-
bated in the same medium with the addition of 200 
 
m
 
M ADP.
The reaction product was converted to cerium-perhydroxide in
glycine-NaOH buffer with H
 
2
 
O
 
2
 
. Subsequently, a diaminoben-
zydine amplification step was carried out to enhance the visibility
of the ATPDase reaction product. Sections not incubated with
ADP or ATP served as negative controls.
 
Statistical Analysis
 
Data were analyzed by graphical representation and by the
Mann Whitney Rank Sum Test where indicated (Sigma Suite
Version 2.0 for Windows 95; Jardel Scientific, San Rafael, CA).
 
Results
 
Quiescent Aortic Endothelial Cells (pEC and hEC) Exert an
Inhibitory Effect on Human Platelet Aggregation Responses In
Vitro.
 
When control platelets were stimulated with stan-
dard agonists, aggregation was a consistent event. However,
in the presence of both pEC and hEC, the aggregation of
washed, gel filtered platelets in response to ADP, collagen,
and low doses of thrombin was totally inhibited in a man- 
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ner consistent with abrogation of aggregation responses.
The EC-associated factor(s) that blocked human platelet
aggregation were found to be cell associated, and could not
be detected in pEC or hEC culture supernatants, confirm-
ing the previously published data on HUVEC by Marcus et al.
(17). This inhibitory factor completely blocked purified
human platelet responses to the agonists in the presence of
pEC in monolayer on the cuvettes, or on bead cultures of
pEC placed into the cuvette in addition to the EC suspen-
sions as tested above (data not shown).
Combinations of human platelet rich plasma and pEC
resulted in a rapid and spontaneous aggregation response.
This was observed to be a xenogeneic phenomenon, as no
platelet aggregation was noted with either hEC or HUVEC
when tested with human platelet rich plasma. This mode of
platelet activation was found to be a result of extensive
complement activation on the xenogeneic EC and throm-
bin generation (28).
 
Characteristics of the EC-associated Inhibitor. 
 
We tested four
of the putative systems associated with EC that block plate-
let aggregation for their involvement in the inhibitory pro-
cess. Incubation of pEC treated with acetylsalicylic acid and
indomethacin with platelets taken from donors who had
ingested aspirin, did not influence the inhibitory properties
of the EC. These data suggested that the cell-associated in-
hibitor was “aspirin insensitive” i.e., did not represent pros-
tenoids and were in accordance with previously published
findings (17). Additionally, the inhibitory effect of EC on
human platelets appeared not to be influenced by known
modulators of NO; hemoglobin, which scavenges NO, and
methylene blue, which inhibits soluble guanylate cyclase,
had no discernible effects on the inhibitory potential of
pEC and hEC.
EC-associated thrombomodulin, because of its anticoag-
ulant potential, was considered to be a potential inhibitor
of thrombin-induced platelet responses in the pEC and
platelet combinations tested. Supernatants which were taken
from pEC and platelets incubated with thrombin (0.1 U/ml)
still contained thrombin, and induced aggregation when
added to platelets alone. These observations indicated that
the interaction of thrombomodulin with thrombin was not
responsible for the observed inhibitory effect of pEC on
platelets (data not shown).
Because of the importance of ADP as an agonist that am-
plifies and propagates platelet activation induced by itself or
other agents (37), experiments were carried out to deter-
mine whether the inhibitory capacity of the xeno- and al-
logeneic aortic EC was dependent upon cellular ATPDase
activity. To this end, ADP-
 
b
 
-S, a structural analog of ADP
(38) that can activate platelet receptors but is not hydro-
lyzed by the ATPDase, was used to induce aggregation of
platelets, both alone and in combination with pEC or hEC.
The profound inhibitory effect of these EC on platelet ag-
gregation was noted when ADP was used as the platelet ag-
onist. However, this pattern of inhibition of platelet aggre-
gation by EC was not observed when ADP-
 
b
 
-S was used
as the agonist (Fig. 1). These data suggest that hydrolysis of
ADP by ATPDase was responsible, at least in part, for the
inhibitory potential of the EC.
 
Characteristics of EC-associated ATPDase.
 
The EC asso-
ciated ATPDase activity was determined by biochemical
and functional parameters. The vascular ecto-enzyme was
confirmed to have E-type ATPDase activity as suggested
by Plesner (19) based on identical substrate specificity for
ATP and ADP, the strict Ca
 
2
 
1
 
 and Mg
 
2
 
1
 
 dependence, and
the patterns of ecto-enzymatic inactivation with various
defined inhibitors (22; Table 1). The inhibitors for P-type
plasma membrane ATPase (ouabain) and alkaline phos-
phatases (levamisole) had little effect on ATPDase enzy-
matic function, whereas sodium azide could block approxi-
mately half the activity. All enzymatic activities reported in
Table 1 are derived by subtracting values obtained with
EGTA from those with Ca
 
2
 
1
 
.
The hydrolysis of radiolabeled ADP to AMP and conse-
quent catalysis to adenosine by confluent, intact pEC was
measured by TLC. ADP was rapidly degraded by the ecto-
enzyme associated with EC. AMP, and then adenosine,
were generated during 30 min incubation with dipyridamole
(10 
 
m
 
M; Fig. 2). Adenosine appearance was probably asso-
ciated with 5
 
9
 
 nucleotidase activity (Fig. 2). These kinetic
determinations were in concordance with those stated for
Figure 1. Effect of pEC on platelet aggregation induced by ADP and
ADP-b-S (an ADP analog resistant to ATPDase activity). Platelets under-
went comparable aggregation responses after stimulation with 1 mM ADP
and 5 mM ADP-b-S. Addition of pEC abrogated platelet responses to
ADP alone, but had minimal effects on ADP-b-S stimulated platelet ag-
gregation. These data indicate a functional ATPDase associated with EC
is responsible, at least in part, for the inhibitory effects on platelet aggrega-
tion in vitro.157 Robson et al.
the pEC ecto-enzyme as determined by another methodol-
ogy (39).
Modulation of EC ATPDase Activity By TNFa In Vitro.
Activation of 10–50 ng/ml pEC or hEC by human recom-
binant TNFa from 1 to 8 h, resulted in rapid loss of the EC
antiaggregatory phenotype and the development of a per-
missive environment for platelet activation in response to
the standard agonists in vitro (Fig. 3). ATPDase activity, as
determined by both [14C]ADP hydrolysis and inorganic
phosphate release from ATP and ADP, showed comparable
patterns of inhibition at the time intervals examined. A
trend towards inhibition was observed as early as 30 to 60
min after TNFa activation, and was maximal by 4 h; statis-
tically significant differences between the ATPDase activi-
ties of the quiescent and TNFa stimulated EC at 2 and 4 h
were confirmed (Fig. 4).
The reconstitution of EC antiplatelet aggregatory prop-
erties (Fig. 3), observed after 18 h of TNFa stimulation,
was paralleled by ATPDase enzymatic activity to levels not
statistically different to those in quiescent EC (data not
shown).
Figure 2. Hydrolysis of [14C]ADP to AMP by EC-associated ATPD-
ase. Radiolabeled ADP hydrolysis to AMP, and consequent catalysis to
adenosine by pEC, was measured by TLC of supernatants from EC cul-
tures. ADP was rapidly degraded and the radio-label appeared as AMP
initially, and then adenosine over a time period of 30 min.
Table 1. Effects of Selected Inhibitors on Vascular EC
ATPDase Activity
Inhibitor
Inhibitor
concentration
Hydrolysis of
200 mM ADP
mM %, median values
None - 100
NaN3 20 48
Ouabain 3 94
Levamisole 1.5 86
AMP 5 80
Vascular EC ATPDase activity was determined by the malachite green
technique as described in Materials and Methods. CA21-dependent free
phosphate release from exogenous ADP was determined at the end of a
10 min incubation with pEC, with or without the specified inhibitors.
All assays were performed in triplicate. Figure 3. ATPDase antiaggregatory activity is modulated by EC re-
sponses to TNFa in vitro. Activation of quiescent porcine EC by 10 ng/ml
human recombinant TNFa from 1 to 8 h in vitro resulted in rapid loss of
the activated EC antiaggregatory phenotype at the time of testing. This
was noted by the development of a permissive environment for platelet
activation in response to 5 mM ADP in vitro. After TNFa stimulation of
EC, reconstitution of functional antiplatelet aggregatory properties was
observed by 18 h.
Figure 4. ATPDase enzymatic activity after EC activation by TNFa.
EC ATPDase activity was determined by measuring inorganic phosphate
release from ADP and ATP. An inhibitory effect was maximal by 4 h after
stimulation of pEC by TNFa as depicted here for ADP (data in graph are
expressed as means and SD; normality test passed). Statistical analysis con-
firmed significant differences to control quiescent EC values at both 2 and
4 h after EC activation; *P ,0.005, Mann Whitney Rank Sum Test. Ex-
periments studying ATPDase activity by [14C]ADP hydrolysis gave similar
results (data not shown).158 Endothelial ATP Diphosphohydrolase and Oxidative Reactions
Expression of EC ATPDase after Cellular Activation In Vitro.
The polyclonal antibody directed to peptide sequences
from porcine aortic ATPDase did not react with ATPDase
antigen as expressed by intact EC by immunocytochemis-
try (data not shown). However, this antibody did recognize
denatured ATPDase from human EC lysates from quies-
cent and TNFa stimulated cells analyzed by Western blot-
ting. Using this technique, we did not observe either dimi-
Figure 5. Effect of EC activation upon ATPDase
antigen expression. (a) Western blotting. The poly-
clonal antibody recognized ATPDase in human EC
preparations purified from quiescent- and TNFa-
stimulated cells by Western blotting. We did not ob-
serve significant diminution of ATPDase antigen ex-
pression, nor evidence for proteolytic degradation,
despite the documented reduction in enzyme activity
at this time point. (b) Immunocytofluorometric anal-
ysis. These plots demonstrate high levels of surface
expression of CD39 on quiescent HUVEC (bold line,
anti-CD39; faint line, isotype control mAb) (A). The
expression of CD39 epitopes on the EC surface was
largely unaltered after TNFa stimulation (10 ng/ml;
B) or direct oxidative stress with H2O2 (100 mM; C).
Cells were analyzed by flow cytometry as described
in Materials and Methods.159 Robson et al.
nution of ATPDase antigen expression, or evidence for
protein degradation, despite the reduction in enzyme activ-
ity in EC stimulated with TNFa at 2 h. (Fig. 5 a).
Surface expression of CD39/ATPDase was confirmed
by cytofluorometric analysis of human EC with anti–CD39
mAb (Fig. 5 b) in concordance with the surface biochemi-
cal activity demonstrated earlier (Fig. 4). After stimulation
of EC with TNFa (10 ng/ml), the expression of CD39
epitopes, as determined by immunocytofluorometric analy-
sis between 2 and 4 h, was largely unaltered. There were
also no changes observed in the levels of surface CD39
staining when TNFa activated EC were examined by im-
munocytochemistry (data not shown).
Endogenous xanthine oxidase and other enzyme systems
in pEC (e.g., NADPH oxidase) elaborate significant levels
of reactive oxygen intermediates after cellular activation.
For example, the generation of H2O2 by pEC after activa-
tion with cytokines, such as TNFa, is 0.015 nmol/min/106
cells (25). In light of the patterns of ATPDase functional
inhibition in the setting of pEC activation and the parallels
with the modulation of thrombomodulin (10), we further
evaluated the effects of exogenous oxidative stress on cell-
associated ATPDase expression in vitro. As demonstrated
by flow cytometry, the exposure of HUVEC to H2O2 (100
mM) for 2 h did not alter the surface expression of CD39
(Fig. 5 b).
Effect of Oxidative Stress on pEC ATPDase Activity In Vitro.
Although no differences in cell surface expression of CD39
were observed by flow cytometry following HUVEC acti-
vation, we tested the hypothesis that ATPDase enzymatic
function could be inhibited by direct exposure to reactive
oxygen intermediates. We observed that exogenous sys-
tems that generated oxidative stress and resulted in EC
membrane lipid peroxidation (data not shown) could, in
turn, significantly inhibit ATPDase activity in vitro. The
reduced capacity of EC directly perturbed by oxidative
stress to express ATPDase activity was demonstrated by
both TLC analysis of radiolabeled ADP hydrolysis and by
estimation of phosphate release from supplemental ADP
(Fig. 6 a; Mann Whitney Rank Sum Test, P 5 0.002).
Further, impressive evidence for the loss of ATPDase func-
tional activity was also derived from the demonstration that
EC exposed to oxidative stress rapidly became unable to
inhibit platelet responses to ADP in vitro (Fig. 6 b).
Figure 6. Effects of oxidative stress on EC ATPDase activity. (a) ATPD-
ase biochemical activity assay. The decreased capacity of pEC directly
perturbed by oxidative stress to express ATPDase activity was demon-
strated by estimation of phosphate release from supplemental ADP by the
malachite green technique. Exogenous xanthine oxidase (XO, 100 mU/ml)
and xanthine (X, 100 mM) markedly inhibited pEC ATPDase activity in a
statistically significant manner after 2 h oxidant exposure (*P 5 0.002;
Mann Whitney Rank Sum Test). This effect could be abrogated by the
supplemental antioxidants superoxide dismutase (SOD; 330 U/ml) and
catalase (1,000 U/ml), confirming the purely oxidant nature of the inhibi-
tion (data are expressed as means and standard deviations; normality test
passed for graphical representation). (b) Platelet inhibitory properties of
ATPDase. Further evidence for the loss of ATPDase functional activity
after exposure to oxidants was derived from the demonstration that pEC
exposed to such reactions for 2 h were unable to inhibit platelet aggrega-
tion responses to ADP 5 mM.
Figure 7. Maintenance of pEC-associated ATPDase activity by anti-
oxidants after TNFa stimulation. Superoxide dismutase (SOD; Cu-Zn
form, 330 U/ml); the hydrogen peroxide scavenger catalase (1,000 U/ml)
and the 21-aminosteroid des-methyl tirilazad (U74389; final concentra-
tion 5 mM) were again used as antioxidants. Such interventions could
protect against the statistically significant TNFa-mediated inhibitory
changes in pEC ATPDase activity, and had minimal positive effects on
quiescent pEC ATPDase levels. Inhibition of ATPDase activity following
TNFa activation was consistently abrogated by these antioxidants (data
are expressed as mean and standard deviations).160 Endothelial ATP Diphosphohydrolase and Oxidative Reactions
Protective Effect of Antioxidants Upon ATPDase Activity.
We next evaluated whether effective combinations of su-
peroxide dismutase (SOD) and catalase, or more novel an-
tioxidants such as 21-amino-steroids (des-methyl tirilazad)
could protect EC against TNFa-mediated changes in ATPD-
ase activity in vitro. The inhibition of ATPDase activity
following TNFa activation was consistently abrogated by
the selected antioxidants (Fig. 7). SOD and catalase were
also able to preserve pEC ATPDase activity following the
addition of the exogenous oxidant systems (Fig. 6 a).
In parallel experiments, the effect of a reducing agent,
b-mercaptoethanol (5 and 10 mM) on ATPDase activity
was studied after TNFa stimulation of pEC. Supplementa-
tion of pEC cultures with b-mercaptoethanol, before cel-
lular activation, was as effective at maintaining enzyme ac-
tivity as the antioxidant combinations.
Loss of Functional ATPDase from Vasculature. Using a cer-
ium-based histochemical method, strongly positive staining
for the ADP hydrolysis reaction product specifically gener-
ated by ATPDase activity, was observed in association with
the vasculature of glomeruli from normal rat kidneys. After
1 h of ischemia and 1 h of subsequent reperfusion, a marked
reduction in staining was noted (Fig. 8, a and b). In parallel,
corresponding light microscopy showed that control glom-
eruli lacked neutrophils, whereas a considerable number of
neutrophils associated with platelet deposits were noted af-
ter the episode of ischemia-reperfusion (Fig. 8, c and d).
Discussion
We have shown that the vascular ATPDase regulates
both allogeneic and xenogeneic platelet aggregation in vitro,
and that this activity is inhibited by EC activation and oxi-
dant exposure. These processes are linked with ischemia-
reperfusion vascular injury. The modulation of ATPDase
activity is observed with cytokine-mediated EC activation
and the associated elaboration of oxidants, or may occur af-
ter direct cellular perturbation with reactive oxygen inter-
mediates. Inhibition of ATPDase was abrogated, at least in
part, by pharmacologically effective levels of the antioxi-
Figure 8. Loss of ATPDase activity during reperfusion injury in vivo. Upper panels show the extent of enzyme histochemical activity (cerium chloride
method) within representative glomeruli of rat kidneys which were (a) freshly harvested, or (b) subjected to 1 h of ischemia and a further hour of reper-
fusion. Compared to the moderate to dense enzyme expression by rat vascular EC in control glomeruli (a), reperfusion injury and associated oxidative
stress reduced ATPDase activity to negligible levels (b); arrows indicate neutrophils within capillary loops of kidney subjected to reperfusion injury.
Lower panels are corresponding Hematoxylin- and Eosin-stained sections, showing (c) good preservation of glomerular structure and absence of leuko-
cytes, and (d) association of reperfusion injury with focal platelet microthrombi which fill some capillary loops and the presence of neutrophils (arrows). All
panels 3200.161 Robson et al.
dant agents tested. Similar beneficial effects on the mainte-
nance of EC enzymatic activity were observed with the re-
ducing agent b-mercaptoethanol. Comparable results have
been described for nucleoside triphosphate hydrolase iso-
zymes from the parasitic protozoan Toxoplasma gondii where
enzyme activity has been found to be activated by dithio-
threitol (40). From evaluating the experimental conditions,
we have postulated that the observed inhibition of EC
ATPDase functional activities could be directly linked to
oxidative stress.
Our observations regarding the ATPDase are compara-
ble to those relating to the other antithrombotic molecules,
the activity of which is lost from the surface of the EC after
exposure to proinflammatory mediators. Thrombomodulin
activity associated with the EC surface is inhibited follow-
ing similar activation responses (3, 10). Additionally, oxida-
tive injury in xenograft rejection has been shown to exac-
erbate the loss of heparan sulfate, observed after the activation
of pEC by xenoreactive antibody and complement (9, 41).
Acetylhydrolase, the plasma enzyme that degrades plate-
let activation factor (PAF), is also rapidly inactivated by ox-
ygen radicals (35). Therefore, platelet activation, in the set-
ting of oxidant stress, would be facilitated by the loss of EC
ATPDase and would be further promoted by increased
PAF. Both increased levels of PAF and the loss of the bio-
logical functions of ATPDase would tend to potentiate in-
jury during vascular inflammatory events.
ATPDases may be considered sensitive to oxidative stress
reactions because of their localization within cellular mem-
branes (19). The documented inhibition of vascular ATPD-
ase activity after adriamycin-mediated injury to rat glomer-
ular endothelium in vivo (18) could represent sensitivity of
the ecto-enzyme to oxidative reactions. Further, the expo-
sure of HUVEC to reactive oxygen metabolites has been
shown to result in depletion of intracellular ATP; this effect
was considered to result from the interference with extra-
cellular catabolism of adenine nucleotides and reduced ade-
nosine entry into cells, although mechanisms were not di-
rectly examined (42).
We were not able to demonstrate any changes in the
levels of surface expressed CD39/ATPDase after either cy-
tokine activation or oxidant perturbation of human EC where
loss of ATPDase function had been demonstrated in paral-
lel (Fig. 5 b). Additionally, no changes were observed in the
ATPDase antigen levels in TNFa-activated EC with the
polyclonal antibody that was shown to recognize denatured
protein of the same molecular size as the native ATPDase
in Western blotting (Fig. 5 a). These findings are consistent
with the hypothesis that the early decrease in ATPDase ac-
tivity is related to oxidative damage, and thus, inactivation
of the ATPDase without apparent proteolytic degradation
or immediate loss from the surface membrane of the EC.
Several of our in vitro findings have been paralleled by in
vivo observations. We have observed the loss of the vascu-
lar ATPDase activity following reperfusion type injury in
rat kidneys where oxidative reactions are of central import.
The process of vascular injury with organ reperfusion or
during xenograft rejection (21) will result in the release of
ATP and ADP from platelets and subendothelium (43, 44).
Both ATP and ADP may activate neutrophils via puriner-
gic type P2y receptors, while ADP triggers platelets through
type P2t receptors (11). ATPDase activity results in hydrol-
ysis of these nucleotides to AMP, which is further degraded
to adenosine. The latter modulates both platelet and neu-
trophil function through adenosine type 2 receptors. ATP
and ADP also trigger PGI2 and NO release via P2y recep-
tors on the endothelium. ATP predominantly stimulates
neutrophils via P2y receptors, and results in the increased
release of reactive oxygen intermediates, which may have
profound effects on platelet reactivity as mediated through
PAF and NO (45, 46). In addition, such induction of oxi-
dative stress by the neutrophils could result in the further
inhibition of the ATPDases blocking the sequential degra-
dation of ATP and ADP, and potentiating inflammation in
the setting of EC activation.
We have already confirmed that the vascular ATPDase
has common identity with the previously described B cell
activation marker designated as CD39 (22); others have re-
cently shown that CD39 has apyrase activity (47). This
membrane protein, CD39, has several potential targets for
oxidative damage since the protein is rich in cysteine, me-
thionine, and tyrosine residues (22, 47).
The direct relevance of CD39/ATPDase in transplanta-
tion biology and in other inflammatory vascular conditions
must remain speculative at this time. It is our belief that
rapid loss of ATPDase activity has an important pathoge-
netic role in the platelet deposition that occurs in the
setting of graft preservation injury and with the repeated
vascular insults associated with organ transplantation. The
awareness that CD39 encodes the vascular ATPDase, and
our findings above, may allow us to express CD39/ATPD-
ase in such a manner that activity is not lost in an inflam-
matory environment.
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